CAM-H2 – New Treatment Option In HER2- Positive Cancer
Time: 11:30 am
day: Day 2 Track A
Details:
- Building on strengths of single domain antibody-based platform
- Evolving landscape in HER2-positive cancer
- Ongoing CAM-H2 Phase I/II clinical study
